Status:
TERMINATED
A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
New York Presbyterian Hospital
Weill Medical College of Cornell University
Conditions:
Bladder Cancer
Eligibility:
MALE
18+ years
Brief Summary
The purposes of this study is to evaluate a new genetic-based test which will identify patients diagnosed with muscle-invasive bladder cancer before their surgery, who might have specific genes, which...
Eligibility Criteria
Inclusion
- Patients in whom pelvic lymph node dissection can be performed;
- Any male and/or female, who is ≥18 years of age;
- Pathological diagnosis of urothelial carcinoma of the bladder;
- Localized muscle-invasive disease defined as clinical stage T2-4aN0M0 tumors;
- Did not receive neoadjuvant therapy;
- No radiographic evidence of metastatic disease on CT scans of the abdomen and pelvis, chest x-ray, or bone scan;
- Informed consent before study participation
Exclusion
- Prior systemic chemotherapy;
- Prior radiation therapy;
- A history of another ongoing malignancy within the past 5 years other than basal cell carcinoma of the skin
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00918008
Start Date
June 1 2009
End Date
May 1 2011
Last Update
March 6 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
2
New York Presbyterian Hospital-Weill Medical College of Cornell University
New York, New York, United States, 10065